# Croatia Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Croatia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Croatia (HRV) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $887.6M - Products: 30 - Buyer markets: 26 - Average CAGR: +37.4% - Global sector size: $749.9B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $310.3B | $552.5M | $115.9B | +30.1% | 22 | +0.2% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $164.9B | $205.2M | $67.9B | +84.6% | 16 | +0.2% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $22.0B | $16.4M | $29.6B | +78.1% | 3 | +0.0% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $16.4B | $3.3K | $29.5B | +54.6% | 1 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $846.9K | $23.0B | +46.9% | 3 | +0.0% | | HS 300220 - Vaccines: for human medicine | $26.1B | $2.9M | $21.8B | +16.1% | 6 | +0.0% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $23.3B | $1.7M | $16.1B | +22.0% | 8 | +0.0% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $29.3B | $11.2M | $15.9B | +91.6% | 6 | +0.0% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $15.4B | $22.8K | $15.5B | +11.0% | 2 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $24.2B | $68.6M | $14.9B | +53.3% | 8 | +0.3% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $7.1M | $8.5B | +39.6% | 3 | +0.0% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $687.7K | $8.0B | +17.7% | 4 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $16.7B | $547.2K | $7.3B | +20.4% | 4 | +0.0% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $5.5B | $25.2K | $7.1B | +0.1% | 2 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $9.3M | $6.1B | +0.5% | 3 | +0.3% | | HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $2.6B | $358.4 | $5.1B | -44.7% | 1 | +0.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $6.9B | $3.8K | $5.1B | +25.3% | 2 | +0.0% | | HS 330300 - Perfumes and toilet waters | $6.6B | $269.3K | $4.1B | +3.6% | 2 | +0.0% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $186.3K | $2.2B | +23.3% | 2 | +0.0% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $3.4K | $2.1B | -18.1% | 1 | +0.0% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $9.4M | $2.0B | +26.3% | 1 | +0.2% | | HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $409.7K | $2.0B | +13.2% | 1 | +0.0% | | HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $30.4K | $1.8B | +14.3% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $53.6 | $1.4B | -14.6% | 1 | +0.0% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $2.4K | $1.4B | +15.0% | 1 | +0.0% | | HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $1.6K | $1.2B | +22.8% | 1 | +0.0% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $38.8 | $1.1B | -39.0% | 1 | +0.0% | | HS 293410 - Heterocyclic compounds: containing an unfused thiazole ring (whether or not hydrogenated) in the structure | $890.3M | $202.0K | $1.1B | +2.1% | 1 | +0.0% | | HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $9.3K | $1.0B | +11.7% | 1 | +0.0% | | HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $117.1K | $989.9M | -3.5% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $148.7B calculated opportunity across 19 products. - Slovenia (SVN): $44.0B calculated opportunity across 7 products. - Switzerland, Liechtenstein (CHE): $37.7B calculated opportunity across 5 products. - Germany (DEU): $32.4B calculated opportunity across 11 products. - Netherlands (NLD): $21.7B calculated opportunity across 7 products. - Belgium (BEL): $20.5B calculated opportunity across 4 products. - China (CHN): $19.1B calculated opportunity across 6 products. - United Kingdom (GBR): $12.2B calculated opportunity across 6 products. - Italy (ITA): $12.1B calculated opportunity across 3 products. - Canada (CAN): $11.8B calculated opportunity across 7 products. - Spain (ESP): $11.5B calculated opportunity across 6 products. - France (FRA): $9.1B calculated opportunity across 5 products. ## Growth stars - HS 300212: +91.6% average CAGR, $15.9B calculated opportunity. - HS 300215: +84.6% average CAGR, $67.9B calculated opportunity. - HS 300214: +78.1% average CAGR, $29.6B calculated opportunity. - HS 293719: +54.6% average CAGR, $29.5B calculated opportunity. - HS 300439: +53.3% average CAGR, $14.9B calculated opportunity. - HS 293359: +46.9% average CAGR, $23.0B calculated opportunity. - HS 293499: +39.6% average CAGR, $8.5B calculated opportunity. - HS 300490: +30.1% average CAGR, $115.9B calculated opportunity. - HS 300420: +26.3% average CAGR, $2.0B calculated opportunity. - HS 382600: +25.3% average CAGR, $5.1B calculated opportunity. ## Diversification opportunities - HS 300490: 22 buyer markets, $115.9B calculated opportunity. - HS 300215: 16 buyer markets, $67.9B calculated opportunity. - HS 382499: 8 buyer markets, $16.1B calculated opportunity. - HS 300439: 8 buyer markets, $14.9B calculated opportunity. - HS 300220: 6 buyer markets, $21.8B calculated opportunity. - HS 300212: 6 buyer markets, $15.9B calculated opportunity. - HS 330499: 4 buyer markets, $8.0B calculated opportunity. - HS 382200: 4 buyer markets, $7.3B calculated opportunity. - HS 300214: 3 buyer markets, $29.6B calculated opportunity. - HS 293359: 3 buyer markets, $23.0B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.